NEW YORK, NY--(Marketwire - August 5, 2008) - Taglich Brothers, Inc. announces it initiated coverage of NeoGenomics, Inc. (OTCBB: NGNM).

NeoGenomics, Inc., headquartered in Fort Myers, FL, also operates laboratories in Nashville, TN and Irvine, CA. The company operates "high complexity" clinical laboratories performing specialized, high-value genetic tests used in the diagnosis and prognosis of various types of cancer. In certain types of cancers, the company's tests also help predict patient responses to various treatments. The company also operates a contract research organization. The company's facilities are licensed under all relevant Federal and state laws, and its services qualify for reimbursement under major government insurance programs, principally Medicare and Medicaid.

Genetic testing analyzes abnormalities from the cell surface inward, specifically in chromosomes, genes and DNA. Genetic testing is much more accurate than traditional clinical laboratory and anatomic pathology testing and can lead to a definitive diagnosis in 98-99% of cases. The rapid growth of genetic testing, which is characterized by high revenues per test and high margins, is reflected in revenue gains experienced by the company and comparable specialized laboratories. This growth is attributed to increases in the number of tests developed to analyze genes discovered to be implicated in cancer, and higher cancer prevalence stemming from the aging of the population.

The complete 19-page report is available at

Taglich Brothers, Inc. is a full-service broker dealer focused exclusively on microcap companies. The Company defines the microcap segment of the equity market as companies with less than $250 million in market capitalization. Taglich Brothers currently offers institutional and retail brokerage services, investment banking and comprehensive research coverage to the investment community.

We do not undertake to advise you as to changes in figures or our views. This is not a solicitation of any order to buy or sell. Taglich Brothers, Inc. is fully disclosed with its clearing firm, Pershing, LLC, is not a market maker and does not sell to or buy from customers on a principal basis. The above statement is the opinion of Taglich Brothers, Inc. and is not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. There may be instances when fundamental, technical and quantitative opinions contained in this report are not in concert. We, our affiliates, any officer, director or stockholder or any member of their families may from time to time purchase or sell any of the above-mentioned or related securities. Analysts and members of the Research Department are prohibited from buying or selling securities issued by the companies that Taglich Brothers, Inc. has a research relationship with, except if ownership of such securities was prior to the start of such relationship, then an Analyst or member of the Research Department may sell such securities after obtaining expressed written permission from the Director of Research. As of the date of this report no Taglich Brothers, Inc. employees had a position in the stock of the Company mentioned in this report: All research issued by Taglich Brothers, Inc. is based on public information. In June, 2008, the company paid a monetary fee of US$6,000, representing payment for the first three of 12 months, for the creation and dissemination of research reports. From September, 2008 through May, 2009, the company will pay a monthly monetary fee of US$2,000, for a total one-year fee of US$24,000 for the creation and dissemination of research reports.

For further information and Taglich Brothers, Inc. ownership data please refer to each individual report.

Contact Information: Contact: Richard Oh Taglich Brothers, Inc. 631-757-1500